Verus Capital Partners LLC Sells 154 Shares of Edwards Lifesciences Co. (NYSE:EW)

Verus Capital Partners LLC lessened its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 3.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,300 shares of the medical research company’s stock after selling 154 shares during the period. Verus Capital Partners LLC’s holdings in Edwards Lifesciences were worth $284,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of EW. Cetera Advisors LLC grew its position in Edwards Lifesciences by 175.1% in the 1st quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock valued at $3,640,000 after acquiring an additional 24,242 shares during the last quarter. BDF Gestion bought a new position in shares of Edwards Lifesciences in the second quarter worth about $5,148,000. Tidal Investments LLC increased its stake in Edwards Lifesciences by 54.7% in the 1st quarter. Tidal Investments LLC now owns 30,245 shares of the medical research company’s stock worth $2,890,000 after buying an additional 10,700 shares during the period. Raymond James & Associates boosted its position in Edwards Lifesciences by 2.8% in the 2nd quarter. Raymond James & Associates now owns 1,825,230 shares of the medical research company’s stock valued at $168,597,000 after buying an additional 50,124 shares during the period. Finally, AIA Group Ltd boosted its position in Edwards Lifesciences by 91.7% in the 3rd quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock valued at $49,461,000 after buying an additional 358,556 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $66.52 on Thursday. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market capitalization of $39.23 billion, a price-to-earnings ratio of 9.60, a PEG ratio of 3.70 and a beta of 1.12. The stock’s 50-day simple moving average is $67.47 and its 200-day simple moving average is $76.51.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.59 EPS. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on EW shares. Wells Fargo & Company decreased their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. TD Cowen cut Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their target price for the stock from $100.00 to $70.00 in a report on Thursday, July 25th. JPMorgan Chase & Co. raised their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Piper Sandler lowered their price objective on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Finally, Evercore ISI cut their target price on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Seventeen analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $75.67.

Insider Activity at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares in the company, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,262,521.36. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 41,250 shares of company stock valued at $2,744,438 in the last ninety days. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.